Do low EPA and OmegaCheck levels suggest a reduced anti-inflammatory reserve?

Eicosapentaenoic acid (EPA) is a critical omega-3 polyunsaturated fatty acid that serves as a fundamental structural and functional component of cellular membranes.

Mechanistic pathways

• Membrane integration and competition: EPA is esterified into the sn-2 position of cell membrane phospholipids, directly competing with arachidonic acid (AA) for enzymatic pathways.
• E-series resolvin synthesis: Upon liberation from the membrane, EPA is oxygenated via modified COX-2 or cytochrome P450 pathways to synthesize 18-hydroxyeicosapentaenoic acid (18-HEPE). This intermediate is subsequently metabolized by leukocyte 5-lipoxygenase (5-LOX) and undergoes epoxide hydrolysis to generate E-series specialized pro-resolving mediators (SPMs), such as RvE1. These mediators target receptors like ChemR23 to limit neutrophil recruitment and promote macrophage-mediated efferocytosis.
• Shift to less inflammatory eicosanoids: EPA also acts as a substrate for COX-2 to produce 3-series prostanoids (e.g., PGE3), which exhibit significantly lower inflammatory potency compared to AA-derived 2-series counterparts.

Clinical and systemic implications

• Biomarker correlation: Systemic blood assessments like OmegaCheck (measuring EPA, DHA, and DPA) are highly correlated ($r = 0.91$) with cellular and red blood cell membrane fatty acid pools.
• Depleted resolution reserve: Below-range EPA and low total OmegaCheck levels directly indicate depleted cell membrane substrate pools. Without adequate upstream EPA, the enzymatic synthesis of 18-HEPE and E-series resolvins is impaired, leaving the body with a compromised biological reserve to actively resolve acute inflammatory challenges.

Bottom line

• Low systemic EPA and OmegaCheck levels directly indicate depleted cell membrane substrate, which impairs the enzymatic synthesis of 18-HEPE and downstream E-series resolvins, ultimately reducing the body's anti-inflammatory and physiological resolution reserve.